Patients with chronic migraine exposed to visual stimulation may have enhanced activity in the spinal trigeminal nucleus and the right superior colliculus compared with healthy individuals.
A recent study evaluated the safety and efficacy of erenumab in patients with episodic migraine who had experienced 2 to 4 previous preventive treatment failures, due to lack of efficacy or intolerable side effects.
Pain experienced by patients during episodic migraine is associated with the occurrence of white matter hyperintensities in the cerebral hemisphere ipsilateral to the pain side.
Researchers have found that monthly subcutaneous injection of galcanezumab significantly reduce migraine headache days.
Complete results from 2 phase 3 trials examining the effects of 2 humanized monoclonal antibodies in patients with episodic and chronic migraine were published simultaneously.
Among individuals diagnosed with episodic migraines, stressful events can accurately predict an individual’s risk of a headache, even before the onset of prodromal symptoms.
In a phase 3 trial, treatment with erenumab reduced migraine frequency, monthly migraine days, and migraine medication use in patients with episodic migraine.
